1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
申请人:H. Lundbeck A/S
公开号:US08969355B2
公开(公告)日:2015-03-03
This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
本公开涉及一种治疗从以下疾病组中选择的方法,包括情感障碍、抑郁症、重性抑郁障碍、焦虑、广泛性焦虑障碍、社交焦虑障碍、强迫症、惊恐障碍和惊恐发作。该方法包括向需要治疗的患者施用化合物I或其药学上可接受的盐的治疗有效量,其中化合物I是1-[2-(2,4-二甲基苯基硫基)-苯基]哌嗪。